A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors.

ABSTRACT: No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n?=?515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n?=?457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n?=?415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ?70%; (II) intermediate risk group: 30%???10-year OS?

SUBMITTER: Pusceddu S 

PROVIDER: S-EPMC5920017 | biostudies-other | 2018 Jun

REPOSITORIES: biostudies-other